ImmunoVaccine Inc.  

(Public, CVE:IMV)   Watch this stock  
Find more results for IMV
Nov 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.35 - 1.50
Open     -
Vol / Avg. 0.00/147,516.00
Mkt cap 67.59M
P/E     -
Div/yield     -
EPS -0.07
Shares 90.02M
Beta 1.17
Inst. own     -
May 12, 2015
Q1 2015 Immunovaccine Inc Earnings Release
Mar 20, 2015
Full Year 2014 Immunovaccine Inc Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -61.53% -74.87%
Return on average equity -93.58% -126.25%
Employees 23 -
CDP Score - -


1344 Summer Street, Suite 412
+1-902-4921819 (Phone)
+1-902-4920888 (Fax)

Website links


Immunovaccine Inc. is a Canada-based clinical stage vaccine and immunotherapy company. The Company discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The Company’s DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The Company has advanced two T cell activation therapies for cancer through Phase I human clinical trials. The Company has research collaborations with research organizations, including the National Institutes of Health (NIH) in the United States. It has licensed the delivery technology to Zoetis, formerly the animal health division of Pfizer, Inc. for the development of vaccines for livestock.

Officers and directors

Marc Mansour Ph.D. Chief Executive Officer, Director
Age: 39
Kimberly Stephens Chief Financial Officer, Corporate Secretary
Frederic Ors Chief Business Officer
Age: 41
Albert James Scardino Non-Executive Chairman
Age: 65
Wade K. Dawe Independent Director
James W. Hall Independent Director
Age: 65
Wayne F. Pisano Independent Director
Alfred A. Smithers Independent Director